Back to news

Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)

Globe Newswire•16/11/2026•03:28 ET
0

Key Highlights

  • ➤ADMIRATION trial failed primary and secondary endpoints in moderate-to-severe atopic dermatitis
  • ➤Bosakitug showed robust TSLP target engagement and immune-biomarker downregulation
  • ➤Bosakitug was generally well tolerated in the Phase 2 trial
  • ➤Aclaris initiated Phase 2b modzatinib trial in lichen planus
  • ➤Aclaris expects ATI-9494 IND filing this quarter and ATI-052 Phase 2b initiation in Q1 2027

Expert Statements

Neal Walker, Chief Executive Officer of Aclaris Therapeutics

“We are disappointed that the ADMIRATION trial did not overcome the historical challenges of addressing atopic dermatitis with an anti-TSLP monoclonal antibody alone.”

Neal Walker, Chief Executive Officer of Aclaris Therapeutics

“We are grateful to the patients and investigators whose participation and commitment made this study possible.”

Neal Walker, Chief Executive Officer of Aclaris Therapeutics

“These results do not change our development priorities, which remain focused on our oral kinase inhibitors and anti-TSLP/IL-4Rα bispecific antibody ATI-052.”

Neal Walker, Chief Executive Officer of Aclaris Therapeutics

“First and foremost, we have initiated the Phase 2b trial of our oral ITK/JAK3 inhibitor modzatinib in lichen planus.”

Neal Walker, Chief Executive Officer of Aclaris Therapeutics

“We’ve also completed the IND-enabling studies for our oral ITK inhibitor ATI-9494 and expect to file the IND this quarter.”

Neal Walker, Chief Executive Officer of Aclaris Therapeutics

“Lastly, we intend to initiate the Phase 2b trial with ATI-052 in eosinophilic esophagitis in the first quarter of 2027.”

Neal Walker, Chief Executive Officer of Aclaris Therapeutics

“We expect to achieve numerous important regulatory, clinical, and data milestones throughout 2027 with each of these assets.”

- The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score from Baseline at Week 24 -

- Aclaris Remains Focused on Prioritizing the Development of its Oral Kinase (ITK) Inhibitors and Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 -

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in